Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase III clinical trial assessing R-phenserine in patients with Parkinson's disease

X
Trial Profile

Phase III clinical trial assessing R-phenserine in patients with Parkinson's disease

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 19 Jul 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Buntanetap (Primary)
  • Indications Parkinson's disease
  • Focus Registrational; Therapeutic Use
  • Sponsors Annovis Bio
  • Most Recent Events

    • 27 Jun 2022 According to an Annovis Bio media release, the company put first parkinson patient in this trial in May, June.
    • 09 Jun 2022 According to an Annovis Bio media release, company expects to start recruitment this summer.
    • 05 Jan 2022 According to Annovis Bio medoia release, the Company expects guidance from the U.S. Food and Drug Administration (FDA) in Q1 of 2022 on the initiation of this phase 3 clinical trial.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top